Biosimilars: Global Markets

Jun 2021| BIO090D| BCC Publishing

Report Highlights

The global biosimilars market should reach $60.1 billion by 2025 from $15.7 billion in 2020 at a compound annual growth rate (CAGR) of 30.9% for the forecast period of 2020 to 2025.

Report Includes

  • 69 data tables and 73 additional tables
  • An updated review and industry insights of the global biosimilars market
  • Analyses of the global market trends, with data from 2018 to 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Highlights of the emerging market regulations, clinical trials, and new products launches; and their impact on the stakeholders in this market
  • Discussion of the biosimilars industry structure, opportunities and complexities, regulatory updates and penetration of biosimilar product classes in various regions worldwide
  • Estimation of current market size and potential growth forecast for biosimilars market, and corresponding market share analysis by product type, application/disease category and geographic region
  • A detailed review of patents issued for biosimilars by different assignee categories
  • Impact analysis of COVID-19 pandemic on the growth of biosimilars market as compared to overall pharmaceuticals industry with respect to clinical trials/approvals
  • Company profiles of the major market players, including Amgen Inc., Boehringer Ingelheim, Cipla Ltd., Dr Reddy’s Laboratories Ltd., Lupin Ltd., Pfizer Inc. and Zydus Cadila

Report Scope

Biosimilar drugs have gained immense popularity because of their impact on the lives of many patients. These drugs belong to several drug classes including hormones, interferons, growth factors (colony stimulating factors, erythropoietin) and monoclonal antibodies, among others. The use of these drugs has aided in the affordable treatment of many life-threatening diseases ranging from cancer and diabetes to chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and others. The high cost of branded biologics has made biosimilars a lucrative alternative for affordable treatment. According to a BCC Research report on biosimilars (BIO090C), the global market for biosimilars is expected to reach close to $20.8 billion by 2022, growing at a CAGR of 30.5%. Other drivers for this market include rising aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

This updated report for BCC Research provides in-depth analysis of the market for biosimilars in a global context, including market forecasts and sales through 2025. This study surveys the market for biosimilars in all the geographic regions including North America, Europe, the developed rest of the world (RoW), and emerging markets. The emerging markets include countries like India, China, Taiwan, Africa and Latin America.

The report provides an analysis of the market for biosimilars in various segments, for instance, by type, by region and by application/disease category. The report will include a detailed overview about the subject wherein the classification of biosimilar drugs along with their approval mechanisms, clinical trials and applications under review are elaborated upon.

The report also provides relevant patent analysis in both the U.S. and the European Union and comprehensive profiles of companies that lead the biosimilar drugs industry. The industry structure, focusing on the important biosimilar drug manufacturers/suppliers and their market shares and product offerings, is analyzed. This report also discusses the current market situation by elaborating upon the market drivers, restraints, challenges and opportunities. Separate chapters discuss the regulatory aspects and clinical trials. The latest news pieces including new products, new indications, mergers and acquisitions in the market are also dealt with in sufficient detail.

Excluded from this report are biobetters, generics of small molecule drugs and the biogenerics pertaining to vaccines and blood products. The different requirements for approval and bioequivalence between generics and biosimilars put them in an entirely different regime.

Frequently Asked Questions (FAQs)

Analyst Credentials

Dr. Kamna Jhamb has more than 13 years of research experience, of which more than four years have been devoted to market research. Before entering the field of market research, she worked as a Research Assistant in Lawrence Berkeley National Lab, CA. With a Ph.D. in Microbial Technology, she has vast knowledge in the areas of microbiology, protein chemistry, and molecular biology. She has several international publications in reputed journals. For BCC Research, Dr. Kamna has written reports spanning topics from healthcare, finance, to biotechnology.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Biosimilars: Global Markets358Free
Chapter- 1: Introduction8Free
Chapter- 2: Summary and Highlights3Free
Chapter- 3: Market and Technology Background36Free
Chapter- 4: Market Breakdown by Type of Biosimilar32Free
Chapter- 5: Market Breakdown by Therapeutic Application38Free
Chapter- 6: Market Breakdown by Region73Free
Chapter- 7: Industry Structure34Free
Chapter- 8: Regulatory Aspects24Free
Chapter- 9: Patent Analysis20Free
Chapter- 10: Clinical Trials11Free
Chapter- 11: Analysis of Market Forces23Free
Chapter- 12: Company Profiles51Free
Chapter- 13: Appendix: Acronyms5Free
Published - Apr-2018| Analyst - Kamna Jhamb| Code - BIO090C

Report Highlights

The global biosimilars market reached nearly $5.5 billion in 2017 and is expected to reach $20.8 billion by 2022, with a compound annual growth rate (CAGR) of 30.5% from 2017 through 2022.

Report Includes

  • 80 data tables and 16 additional tables
  • An overview of the global market for biosimilars
  • Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • A look at biosimilar product classes in various regions worldwide, as well as the worldwide pipeline for biosimilars
  • Detailed analysis of the emerging framework in regulated markets, as well as comparisons of biosimilar guidelines in Europe, the U.S., Japan, Canada, as well the guidelines developed by the World Health Organization
  • Technology trends and patent analyses
  • Comprehensive company profiles of key players in the market, including Allergan Plc., Bioton S.A., Cinnagen, Emcure Pharmaceuticals Ltd., LG Life Sciences, Neuclone and Pfizer Inc.
Published - Jan-2015| Analyst - Shalini Shahani Dewan| Code - BIO090B

Report Highlights

The global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014. The market is expected to reach nearly $4.0 billion by 2019, with a compound annual growth rate (CAGR) of 15% from 2014 through 2019.

Report Includes

  • An overview of the global market for biosimilars.
  • Analyses of global market trends, with data from 2012 through 2014, and projections of CAGRs through 2019.
  • A look at biosimilar product classes in various regions worldwide, as well as the worldwide pipeline for biosimilars.
  • Detailed analysis of the emerging regulatory framework in regulated markets as well as comparisons of biosimilar guidelines in Europe, the U.S., Japan, Canada, and the guidelines developed by WHO.
  • Technology trends and patent analysis.
  • Comprehensive profiles of key players in the market.
Published - May-2012| Analyst - Syamala Ariyanchira| Code - BIO090A

Report Highlights

The global market for biosimilars reached $1.7 billion in 2010 and $2.5 billion in 2011. The market is expected to reach $3.6 billion by 2016, a compound annual growth rate (CAGR) of 7.7%.

Biosimilars: Global Markets

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
RELATED REPORTS